title: Cardiac sympathetic nervous system imaging with123I-meta-iodobenzylguanidine: Perspectives from Japan and Europe.
abstract: Cardiac sympathetic nervous system dysfunction is closely associated with risk of serious cardiac events in patients with heart failure (HF), including HF progression, pump-failure death, and sudden cardiac death by lethal ventricular arrhythmia. For cardiac sympathetic nervous system imaging,123I-meta-iodobenzylguanidine (123I-MIBG) was approved by the Japanese Ministry of Health, Labour and Welfare in 1992 and has therefore been widely used since in clinical settings.123I-MIBG was also later approved by the Food and Drug Administration (FDA) in the United States of America (USA) and it was expected to achieve broad acceptance. In Europe,123I-MIBG is currently used only for clinical research. This review article is based on a joint symposium of the Japanese Society of Nuclear Cardiology (JSNC) and the American Society of Nuclear Cardiology (ASNC), which was held in the annual meeting of JSNC in July 2016. JSNC members and a member of ASNC discussed the standardization of123I-MIBG parameters, and clinical aspects of123I-MIBG with a view to further promoting123I-MIBG imaging in Asia, the USA, Europe, and the rest of the world.
authors.affiliation: Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, Japan.
authors.forename: Kenichi
authors.initials: K
authors.lastname: Nakajima
authors.affiliation: Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
authors.forename: Arthur J H A
authors.initials: AJHA
authors.lastname: Scholte
authors.affiliation: Department of Cardiology, Hakodate Goryokaku Hospital, Hakodate, Japan.
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Nakata
authors.affiliation: Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
authors.forename: Aukelien C
authors.initials: AC
authors.lastname: Dimitriu-Leen
authors.affiliation: Department of Cardiology, Tokyo Medical University, Tokyo, Japan.
authors.forename: Taishiro
authors.initials: T
authors.lastname: Chikamori
authors.affiliation: Quanta Diagnóstico & Terapia, Curitiba, PR, Brazil.
authors.forename: João V
authors.initials: JV
authors.lastname: Vitola
authors.affiliation: Diagnostic and Therapeutic Nuclear Medicine, National Institute of Radiological Sciences, 4-9-1 Anagawa, Inage-Ku, Chiba, 263-8555, Japan. yoshinaga.keiichiro@qst.go.jp.
authors.forename: Keiichiro
authors.initials: K
authors.lastname: Yoshinaga
mesh_terms: D019797:3-Iodobenzylguanidine; D057791:Cardiac Imaging Techniques / Q000379:methods*; D003943:Diagnostic Techniques, Neurological; D005060:Europe; D019317:Evidence-Based Medicine; D006321:Heart / Q000000981:diagnostic imaging* / Q000294:innervation*; D006331:Heart Diseases / Q000000981:diagnostic imaging*; D006801:Humans; D007564:Japan; D019275:Radiopharmaceuticals; D013564:Sympathetic Nervous System / Q000000981:diagnostic imaging*
chemical_list: D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine
keywords: 123I-MIBG; Arrhythmia; guidelines; heart failure; sympathetic nervous system